TIMP2 and Bloom syndrome: TIMP-1 and TIMP-2 expression levels were significantly increased in the BLM group compared to those of the control group; by contrast, ACE2-uMSC treatment reduced TIMP-1 and TIMP-2 expression levels significantly.